目前和新兴的恶性纤维性囊细胞瘤/不分化形肉瘤的全身治疗选择
Shinji Miwa1, Norio Yamamoto2, Katsuhiro Hayashi2
1Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-Machi, Kanazawa, 920-8640, Japan. smiwa001@yahoo.co.jp.
International journal of clinical oncology
|May 14, 2025
概括
不分化的多形肉瘤 (UPS) /恶性纤维细胞瘤 (MFH) 是一种常见的软组织肉瘤. 新的全身治疗方法,包括向药物和免疫检查点抑制剂,对转移性疾病有希望,改善了超越传统化疗的结果.
科学领域:
- 在瘤学瘤学.
- 医学瘤学 医学瘤学
- 肉瘤研究研究 肉瘤研究
背景情况:
- 不分化形肉瘤 (UPS),也称为恶性纤维细胞瘤 (MFH),是第二常见的软组织肉瘤.
- 标准治疗包括手术,放射和化疗,对于可切除疾病有更好的结果.
- 转移性UPS/MFH的结果不令人满意,常规化疗反应率仅为27%至33%.
研究的目的:
- 审查最近对UPS/MFH系统治疗的临床研究.
- 讨论新型抗癌药物的疗效,包括分子向药物和免疫检查点抑制剂.
- 为突出转移性UPS/MFH患者的新兴治疗选择.
主要方法:
- 审查最近的临床研究和试验.
- 对UPS/MFH的系统性治疗策略的分析.
- 评估常规化疗,分子向药物和免疫检查点抑制剂.
主要成果:
- 传统化疗在转移性UPS/MFH中显示出有限的疗效.
- 分子向药物和免疫检查点抑制剂正在成为有希望的全身治疗方法.
- 在早期试验中,观察到免疫检查点抑制剂与多克索鲁比辛结合的高响应率.
结论:
- 系统性治疗对于管理转移性UPS/MFH至关重要.
- 像免疫检查点抑制剂这样的新型药物提供了更好的结果.
- 需要进一步的大规模研究来确认组合疗法的疗效.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Tumor Immunotherapy
406
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
406


